Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.63 |
| ▸ | EGFR | P00533 | 4/20 | 0.54 |
| ▸ | RET | P07949 | 11/20 | 0.49 |
| ▸ | KDR | P35968 | 9/20 | 0.49 |
| ▸ | KIF5B | P33176 | 9/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30032092 | 1.00 | ENPP1 (0.63) | ENPP1EGFRRETKDRKIF5B | |
| Hydrochloric Acid SCHEMBL28108173 | 0.98 | ENPP1 (0.61) | ENPP1EGFRRETKDRKIF5B | |
| SCHEMBL30054610 | 0.93 | ENPP1 (0.63) | ENPP1EGFRRETKDRKIF5B | |
| SCHEMBL296984 | 0.93 | ENPP1 (0.63) | ENPP1EGFRRETKDRKIF5B | |
| Acetic Acid SCHEMBL3170544 | 0.93 | ENPP1 (0.56) | ENPP1EGFRRETKDRKIF5B | |
| SCHEMBL29359187 | 0.86 | ENPP1 (0.81) | ENPP1EGFRRETKDRRAF1 | |
| SCHEMBL364049 | 0.86 | ENPP1 (0.81) | ENPP1EGFRRETKDRRAF1 | |
| SCHEMBL6160435 | 0.86 | ENPP1 (0.84) | ENPP1EGFRRETKDRKIF5B | |
| Hydrochloric Acid SCHEMBL3526531 | 0.84 | ENPP1 (0.79) | ENPP1EGFRKDR | |
| SCHEMBL24037763 | 0.84 | ENPP1 (0.68) | ENPP1EGFRRETKDRKIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111662273-A | Preparation method of tyrosine kinase inhibitor AZD3759 | 通化师范学院 | 2020-09-15 | — | — | CN | claimed |
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-27 | — | — | US | claimed |
| US-9624179-B1 | Quinazoline derivative Lu1501 and preparing method and application thereof | Nanjing General Hospital of Nanjing Military Region of PLA (CN) | 2017-04-18 | — | — | US | claimed |
| CN-122029158-A | EGFR inhibitors | 缆图药品公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| WO-2025080784-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4506343-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2025-02-12 | — | — | EP | disclosed |
| WO-2005012290-A1 | PIPERIDYL-QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1487806-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | Astrazeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004043472-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2003082831-A1 | 4-ANILINO QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114027-A1 | NOVEL QUINAZOLINE DERIVATIVE LU1501 AND PREPARING METHOD AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, SKP1 | ENPP1 4315/4885EGFR 3014/4885RET 3491/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | ENPP1 2077/4885EGFR 1/4885RET 50/4885 |
| US-20250206760-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | WEE1, WEE2, ERBB2 | ENPP1 1404/4885EGFR 5/4885RET 111/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | ENPP1 1726/4885EGFR 1/4885RET 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.